DocMorris launches approx. CHF 200 million Convertible Bonds due 2029 – Biotech Investments

DocMorris AG / Key word(s): Bond

17-Apr-2024 / 17:46 CET/CEST

Release of an ad hoc announcement pursuant to Art. 53 LR

The issuer is solely responsible for the content of this announcement.

Under the following link you will find our press release about launching an offering of convertible bonds:

https://ir-corporate.docmorris.com/en/investor-relations/convertible-bonds-2024

End of Inside Information

After stock slides, Amgen addresses bone density talk on obesity drug

A lot of Amgen’s future rides on its experimental obesity medicine MariTide. At least in the minds of investors. Ahead of the biopharma’s most critical

November 14, 2024

Tackling Climate Change Starts With a Focus on Health, Lancet Report Says

The eighth Lancet Countdown report — a collaboration between scientists and health practitioners from around the world — paints a dire picture of continued inaction

November 15, 2023

Mainz Biomed Reports Full Year 2023 Financial Results – Biotech Investments

Issuer: Mainz BioMed N.V. / Key word(s): Annual Results 09.04.2024 / 14:01 CET/CEST The issuer is solely responsible for the content of this announcement. Mainz

April 10, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.